Elevance Health reported quarterly revenue of $50,181 million and diluted earnings per share of $8.00, with revenue rising modestly year-over-year while EPS declined. The results reflect higher premiums and investment income driving top-line growth, offset by lower operating and net income. Management noted operational initiatives and membership shifts influencing near-term performance.
Financial Highlights
Total revenues: $50,181 million, up $1,290 (2.6%) versus prior year, driven by higher premiums and investment income.Gross Profit (reported as Income before income tax expense): $2,304 million, down $493 (17.6%) versus prior year.Operating gain (reportable segments’ operating gain): $2,086 million, down $1,084 (34.2%) versus prior year.Net income: $1,760 million, down $424 (19.4%) versus prior year.Diluted shareholders’ earnings per share: $8.00, down $1.61 (16.8%) versus prior year.
Business Highlights
Revenue growth drivers: Operating revenue rose 1.5% year-over-year to $49.5 billion, led by premium rate increases and growth in CarelonRx product revenue.Membership shift: Total medical membership declined 0.9% to 45.4 million, with Medicaid and Medicare Advantage attrition amid redeterminations.Brand and channel expansion: Expanded Public Exchange presence with planned entry in Florida, Maryland, and Texas in 2025 and Washington in 2026; continued growth in employer fee‑based business and vision/dental lines.Operational transformation: Launched a 2026–2027 Transformation Program to simplify the organization, modernize IT and AI capabilities, and execute workforce realignments.CarelonRx and Carelon Services: CarelonRx saw higher average revenue per script; Carelon Services expanded via risk‑based specialty and behavioral health offerings.
Original SEC Filing: Elevance Health, Inc. [ ELV ] – 10-Q – Apr. 22, 2026
Disclaimer
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.